In vivo administration of O6-benzylguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine, but does inhibit P450-dependent activation of dacarbazine

Carcinogenesis

Volumn 21, Issue 4, 2000, Pages 593-598

  Toft, Neil J ^a   Sansom, Owen J ^a   Brookes, Roger A ^b   Arends, Mark J ^a   Wood, Michelle ^c   Margison, Geoffrey P ^c   Winton, Douglas J ^b   Clarke, Alan R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; ALKYLATING AGENT; CISPLATIN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DACARBAZINE; METHYLNITRONITROSOGUANIDINE; METHYLNITROSOUREA; METYRAPONE; MUTAGENIC AGENT; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CHEMICAL MUTAGENESIS; CONTROLLED STUDY; CRYPT CELL; DEALKYLATION; DNA ADDUCT; DNA DAMAGE; METABOLIC ACTIVATION; MOUSE; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE;

EID: 0034094390     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/21.4.593     Document Type: Article

References (38)

1. Clarke, A.R., Howard, L.A., Harrison, D.J. and Winton, D.J. (1997) p53 mutation frequency and apoptosis in the murine small intestine. Oncogene, 14, 2015-2018.
2. Merritt, A.J., Allen, T.D., Potten, C.S. and Hickman, J.A. (1997) Apoptosis in small intestinal epithelia from p53-null mice: evidence for delayed, p53-independent G2/M-associated cell death after γ-irradiation. Oncogene, 14, 2759-2766.
3. Potten, C.S., Wilson, J.W. and Booth, C. (1997) Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells, 15, 82-93.
4. 6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent. Oncogene, 12, 693-697.
5. 6-alkylguanine. FASEB J., 6, 2302-2310.
6. 6-alkylguanine-DNA-alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res., 50, 6119-6129.
7. 6-methylguanine-DNA methyltransterase in C3H/10T1/2 cells by X-rays is inhibited by nitrogen. Carcinogenesis, 9, 679-681.
8. 6-alkylguanine-DNA alkyltransferase. Science, 259, 219-222.
9. Liu, L., Lee, K., Markowitz, S. and Gerson, S.L. (1996) Differential sensitivity of human and mouse alkyltransferase to BeG using a transgenic model. Cancer Res., 56, 1880-1885.
10. Sanderson, B.J. and Shield, A.J. (1996) Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat. Res., 355, 41-57.
11. Karran, P. and Bignami, M. (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays, 16, 833-839.
12. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl Acad. Sci. USA, 93, 6443-6447.
13. Toft, N.J., Winton, D.J., Kelly, J., Howard, L.A., Dekker, M., te Riele, H., Arends, M.J., Wyllie, A.H., Margison, G.P. and Clarke, A.R. (1999) Msh2 status modulated both apoptosis and mutation frequency in the murine small intestine. Proc. Natl Acad. Sci. USA, 96, 3911-3915.
14. 6-alkylguanine-DNA-alkyltransferase activity by BeG provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl Acad. Sci. USA, 87, 5368-5372.
15. 6-alkylguanine-DNA alkyltransferase by BeG. Biochemistry, 32, 11998-12006.
16. 6-alkylguanine-DNA-alkyltransferase activity to temozolomide and BCNU. Br J. Cancer, 73, 1049-1052.
17. Dolan, M.E., Pegg, A.E., Moschel, R.C. and Grindey, G.B. (1993) Effect of BeG on the sensitivity of human colon tumour xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem. Pharmacol., 46, 285-290.
18. Dollery, C. (1991) Dacarbazine. In Dollery, C. (ed.) Therapeutic Drugs. Churchill Livingstone, London, UK, Vol. 1, pp. D1-D3.
19. Stevens, M.F., Hickman, J.A. Langdon, S.P., Chubb, D., Vickers, L., Stone, R., Baig, G., Goddard, C., Gibson, N.W., Slack, J.A., Newton, C., Lunt, E., Fizames, C. and Lavelle, F. (1987) Antitumour activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res., 47, 5846-5852.
20. Mudipalli, A., Nadadur, S.S., Maccubbin, A.E. and Gurtoo, H.L. (1995) Mutations induced by dacarbazine activated with cytochrome P-450. Mutat. Res., 327, 113-120.
21. Denny, B.J., Wheelhouse, R.T., Stevens, M.F., Tsang, L.L. and Slack, J.A. (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry, 33, 9045-9051.
22. Winton, D., Blount, M.A. and Ponder, B.A. (1988) A clonal marker induced by mutation in mouse intestinal epithelium. Nature, 333, 463-466.
23. Brugal, G., Dye, R., Krief, B., Chassey, J.-M., Tanke, H. and Tucker, J.E. (1992) HOME: Highly Optimized Microscope Environment. Cytometry, 13, 109-116.
24. Clarke, A.R., Gledhill, S., Hooper, M.L., Bird, C.C. and Wyllie, A.H. (1994) p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene, 9, 1767-1773.
25. Dollery, C. (1991) Metyrapone. In Dollery, C. (ed.) Therapeutic Drugs. Churchill Livingstone, London, UK, Vol. 2, pp. M176-M180.
26. Lacal, P.M., D'Atri, S., Orlando, L., Bonmassar, E. and Graziani, G. (1996) In vitro inactivation of human O6-alkyltransferase by antitumour triazene compounds. J. Pharmacol. Exp. Ther., 279, 416-422.
27. Dolan, M.E. and Pegg, A.E. (1997) O6-Benzylguanine and its role in chemotherapy. Clin. Cancer. Res., 3, 837-847.
28. Newell, D., Gescher, A., Harland, S., Ross, D. and Rutty, C. (1987) N-Methyl antitumour agents: a distinct class of anticancer drugs? Cancer Chemother. Pharmacol., 19, 91-102.
29. D'Incalci, M. (1994) Metabolism of triazine anticancer agents. In Powis, G. (ed.) International Encyclopedia of Pharmacology and Therapeutics. Pergamon Press, Oxford, UK, pp. 157-165.
30. Meer, L., Janzer, R.C., Kleihues, P. and Kolar, G.F. (1986) In vivo metabolism and reaction of DNA with the cytostatic agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DITC). Biochem. Pharmacol., 35, 3243-3247.
31. 6-alkylguanine-DNA-alkyltransferase. Cancer Res., 54, 5123-5130.
32. Nebert, D.W. and Weber, W.W. (1990) Pharmacogenetics. In Pratt, W.B. and Taylor, P. (eds) Principles of Drug Action: The Basis of Pharmacology. Churchill Livingstone, New York, NY, pp. 469-531.
33. Roy, S.K., Korzekwa, K.R., Gonzalez, F.J., Moschel, R.C. and Dolan, M.E. (1995) Human liver oxidative metabolism of O6-Benzylguanine. Biochem. Pharmacol., 50, 1385-1389.
34. Reid, J.M., Kuffel, M.J., Miller, J.K., Rios, R. and Ames, M.M. (1999) Metabolic activation of Dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2 and CYP2E1. Clin. Cancer Res., 5, 2192-2197.
35. Kurpad, S.N., Dolan, M.E., McLendon, R.E., Archer, G.E., Moschel, R.C., Pegg, A.E., Bigner, D.D. and Friedman, H.S. (1997) Intraarterial BeG enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chlororthyl)-1-nitrososurea. Cancer. Chemother. Pharmacol., 39, 307-316.
36. 6-alkylguanine-DNA-alkyltransferase on the frequency and spectrum of mutations induced by N-methyl-N′-nitro-N-nitrosoguanidine in the HPRT gene of diploid human fibroblasts. Mutat. Res., 250, 397-409.
37. 6-alkylguanine-DNA-alkyltransferase. Mutat. Res., 307, 67-81.
38. Chinnasamy, N., Rafferty, J.A., Hickson, I., Ashby, J., Tinwell, H., Margison, G.P., Dexter, T.M. and Fairbairn, L.J. (1997) BeG potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in the mouse bone marrow. Blood, 89, 1566-1573.